文献速递炎症性肠病

阿达木单抗免疫原性与药物浓度时间依赖性的前瞻性观察评估:POETIC研究

Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study.
PubMed 文献 · Am J Gastroenterol · 2018-06-05

POETIC研究对98例起始阿达木单抗的克罗恩病患者进行前瞻性家访随访(中位44周,621份血清),33例(32%)产生抗阿达木单抗抗体(AAA),55%在2周内、79%在14周内出现;诱导期AAA与原发性无应答强相关(OR=5.4,95%CI 1.6-17.8,p=0.005);29例亚组显示 trough 与 trough 间药物及AAA水平相似。

要点

  • 33例(32%)产生AAA,其中55%早在第2周、79%在第14周出现。
  • 诱导期AAA与原发性无应答相关(OR=5.4,95%CI 1.6-17.8,p=0.005)。
  • 29例亚组中,单周期四个时间点的药物与AAA水平似乎相当。

核心结论

  • 前瞻性序贯随访发现AAA出现早于既往认识,且对原发性而非继发性无应答的影响可能更明显。
  • 药物与AAA水平在 trough 和注射间期相似,可简化阿达木单抗治疗药物监测。

研究设计与样本

  • 前瞻性观察研究,对98例起始阿达木单抗的克罗恩病患者进行医生家访(诱导期、每3个月及复发时),中位随访44周,分析621份血清。
  • 与平行前瞻性英夫利西单抗治疗克罗恩病队列比较。
  • 29例亚组比较 trough 与 trough 间水平。

主要发现

  • 33例(32%)产生AAA;18/33(55%)早在第2周、26/33(79%)在第14周出现。
  • 诱导期AAA与原发性无应答相关(OR=5.4,95%CI 1.6-17.8,p=0.005)。
  • AAA形成率随时间显著低于抗英夫利西单抗抗体(ATI)(p=0.01),AAA特异性更高:85%的AAA事件与失去应答相关 vs ATI的58%(p=0.01)。
  • 29例(有AAA n=8,无AAA n=21)单周期四个时间点药物与AAA水平似乎相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Adalimumab is usually self-injected at home, making prospective serial-sampling studies challenging and scarce. This has led to a gap in knowledge about evolution of anti-adalimumab antibodies (AAAs) over time and its correlation with clinical and inflammatory outcomes. METHODS: A program for home visits by physicians at induction, every 3 months and at event of relapse, was established prospectively for Crohn's disease (CD) patients. At each visit, patients' clinical scores were determined and sera were obtained for C-reactive protein, drug, and AAA levels. This cohort was compared to a parallel prospective cohort of infliximab-treated CD patients. In a subgroup of 29 patients, trough and in-between-trough levels were compared, to elucidate the importance of timing of sampling during the injection cycle. RESULTS: Ninety-eight CD patients starting adalimumab were prospectively followed (median follow-up 44 weeks) and 621 serum samples were analyzed. Thirty-three patients (32%) developed AAA; 18/33 (55%) of them as early as week 2, and 26/33 (79%) by week 14. Induction period AAAs were strongly associated with primary non-response (odds ratio (OR) = 5.4, 95% confidence interval (CI): 1.6-17.8, p = 0.005). As compared to antibodies-to-infliximab (ATI), AAA formation rate over time was significantly lower (p = 0.01) and AAA were much more specific-85% of AAA events were associated with loss-of-response compared with 58% rate for ATI (p = 0.01). In 29 patients sampled serially during an injection cycle, levels of drug and AAA seemed comparable between four time-points during a single cycle both in patients with or without AAA (n = 8, n = 21, respectively). CONCLUSIONS: When followed prospectively and serially, AAAs are found to arise earlier than previously appreciated and their impact may be more pronounced for primary rather than secondary, non-response. Drug and AAA levels were similar both at trough and in-between injections, enabling to simplify therapeutic drug monitoring of adalimumab.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Ungar B, Engel T, Yablecovitch D, et al. Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study. Am J Gastroenterol. 2018. PMID: 29867175. doi:10.1038/s41395-018-0073-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。